



Number : 2240/BaliMedJ/Denpasar-Bali/2022

Attachment : -

About : Confirmation Letter

Denpasar, 1 November 2022

To whom it may concern,

I, as the Editor in Chief of **Bali Medical Journal (BaliMedicalJournal.org)**  
**(Indexed by Scopus Elsevier and Web of Science, Clarivate Analytics),**  
at this moment declare that:

Published Manuscript in Bali Medical Journal with Title :

**Comparison of direct medical cost between ramipril and candesartan in hospitalized acute decompensated heart failure at West Nusa Tenggara Regional Hospital**

**Author :**

**Nurul Qiyaam, Baiq Leny Nopitasari, Cyntiya Rahmawati,  
Baiq Nurbaety, Emasiska Ajeng Pratiwi**

Pharmacy Department, Faculty of Medicine,  
Universitas Muhammadiyah Mataram, Indonesia

Published in the Bali Medical Journal Volume 9 Number 2 2020  
(<https://www.balimedicaljournal.org/index.php/bmj/article/view/1871>)

Has gone through the process of Proofreading, editing and Review  
the manuscript before being published.

**Agreed/Menyetujui by:**

**Bali Medical Journal**

The image shows the logo of Bali Medical Journal (BMJ) in blue, followed by a handwritten signature in black ink.

**Prof. Dr. dr. Sri Maliawan, Sp.BS (K)**  
**Editor in Chief**

# Comparison of direct medical cost between ramipril and candesartan in hospitalized acute decompensated heart failure at West Nusa Tenggara Regional Hospital

*by* Qiyaam Nurul

---

**Submission date:** 23-Jun-2020 12:35AM (UTC+0700)

**Submission ID:** 1348143528

**File name:** translate.docx (52.14K)

**Word count:** 3624

**Character count:** 20478

## Comparison of direct medical cost between ramipril and candesartan in hospitalized acute decompensated heart failure at West Nusa Tenggara Regional Hospital

Nurul Qiyaam<sup>1\*</sup>, Baiq Leny Nopitasari<sup>1</sup>, Cyntiya Rahmawati<sup>1</sup>, Baiq Nurbaety<sup>1</sup>, Emasiska Ajeng Pratiwi<sup>1</sup>

<sup>1</sup>Pharmacy Department, Faculty of Medicine, Universitas Muhammadiyah Mataram, Indonesia

\*Correspondence to: [nuqi.gra@gmail.com](mailto:nuqi.gra@gmail.com)

### Abstract

**Introduction:** Pharmacoeconomy is the field of study regarding costs analysis associated with the use of drugs in health care. The purpose of pharmacoeconomics is to compare a different drug used in the treatment with the same condition or can be the opposite, i.e. comparing different treatments in different circumstances. The purpose of this study is to determine and compare the average efficiency of direct medical costs between ramipril and candesartan combination drug in hospitalized heart failure patients with a payer perspective at the West Nusa Tenggara Regional General Hospital, Mataram, Indonesia.

**Method:** This study is part of an economic evaluation of direct medical cost analysis research in hospitalized heart failure patients with a payer perspective. Study design using a retrospective approach involving 45 patients with heart failure who met the study inclusion criteria and exclusion criteria. Independent t-test was used to compare the direct medical cost between ramipril and candesartan.

**Results:** The average gross total cost of using ramipril combination was Rp. 4,197,011 while the average total cost of using candesartan combination was Rp. 3,099,088. These results indicate there are savings in the average total cost of treatment for heart failure using candesartan that is Rp. 1,097,923. Candesartan combination provides the lowest value and is a more efficient choice compared to ramipril combination. Meanwhile, after t-test comparison reveal no significant different average direct medical costs in patients using the ramipril combination compared with the candesartan combination ( $p>0.05$ ).

**Conclusion:** The results of this study indicate that there is no significant difference between the average direct medical costs in patients using ramipril compared with candesartan combination.

**Keywords:** heart failure, ramipril, candesartan, cost analysis, direct medical costs.

### Introduction

The heart is the most important organ in circulation. The heart works to pump blood throughout the body to meet the body's metabolic needs at all times, both at rest and work. Most sufferers live after having a heart attack but then suffer heart failure.<sup>1,2</sup> Heart failure is a clinical syndrome caused by structural and/or functional abnormalities. Heart failure is a growing problem

throughout the world, with more than 20 million people affected by heart failure.<sup>3-5</sup> In developed countries the prevalence of heart failure in the adult age group reaches 2% of the population.<sup>6</sup> The prevalence of heart failure increases with age and affects 6-10% of people over 65 years.<sup>7-9</sup>

The World Health Organization (WHO) notes that 17.9 million people worldwide die from cardiovascular disorders with a percentage of 31% of deaths worldwide. More than 75% of cardiovascular sufferers occur in low and middle-income countries, and 80% of cardiovascular deaths are caused by heart attacks and strokes.<sup>10</sup> In Indonesia, as many as 13,395 people with heart failure undergoing hospitalization, while as many as 16,431 people were undergoing outpatient treatment in all hospitals around Indonesia. In 2018 the results of Basic Health Research showed that the incidence of heart failure increased by 1.5% in Indonesia. While in the West Nusa Tenggara region the prevalence is 0.8%.<sup>11</sup>

The additional cost-effectiveness ratio to expand the coverage of all heart failure patients is \$ 9,700 per life-year gained obtained in the base case. An analysis of the worst case of heart failure assuming simultaneous conservative results in an additional cost-effective ratio of \$ 110,000 per life-year gained. In a probabilistic sensitivity analysis, 99.74% of the possible additional ratios of cost-effective heart failure that were <\$ 50,000 per life-year gained.<sup>12,13</sup> The cost of treatment is a very important issue for developing countries like Indonesia. One that affects the amount of the cost of handling heart failure is the type of drug used. Therefore in the treatment of heart failure a rational and comprehensive treatment is needed to achieve optimal medical service.<sup>14-16</sup>

Pharmacoeconomics is the field of study regarding costs analysis associated with the use of drugs in health care. The purpose of pharmacoeconomics is to compare a different drug used in the treatment with the same condition or can be the opposite, ie comparing different treatments in different conditions.<sup>17</sup> The results of the pharmacoeconomics can be used as a reference or assist policymakers in determining choices for available treatment alternatives so that health services become more efficient and economical. The study aims to determine and compare the average efficiency of direct medical costs between ramipril and candesartan combination drug in hospitalized heart failure patients with a payer perspective at the West Nusa Tenggara Regional General Hospital, Mataram, Indonesia.

## Method

This study is part of a hospital economic evaluation of direct medical cost analysis in acute decompensated heart failure hospitalization. Study design using a retrospective approach with a payer's perspective.<sup>18</sup> The inclusion criteria in this study were patients with main diagnoses of acute decompensated heart failure who were hospitalized in West Nusa Tenggara Regional Hospital who were seeking treatment in the period 2018.

The type of data in this study is secondary data from hospital information system (SIRS), where the data obtained was the primary diagnosed heart failure patient data that met the patient criteria in the study which included age, sex, concomitant diseases and use of combination of

18 ramipril (furosemide 40 mg, spironolactone 25 mg, bisoprolol 5 mg, ramipril 5 mg) or using a combination of candesartan (furosemide 40 mg, spironolactone 25 mg, bisoprolol 5 mg, candesartan 16 mg) West Nusa Tenggara Regional Hospital 2018. The criteria used in assessing costs is the comparison between heart failure patients using the combination of ramipril compared to candesartan combination. A total of 240 patients diagnosed with heart failure who received treatment at West Nusa Tenggara Regional Hospital in 2018, 45 samples were obtained that met the inclusion criteria, 33 patients were using the Ramipril combination and 12 patients using the candesartan combination.

27 Statistical analysis in this study using SPSS version 21.0 (IBM Corporation, Armonk, NY, USA). Independent t-test was used to compare direct medical cost between ramipril and candesartan combination. All value considered significant if  $p < 0.05$ .

## Result

### Characteristics of the study

Table 1. Clinical characteristics

Characteristics	Drugs combination		Total (n=45)		Percentage (%)	
	Ramipril	Candesartan	Ramipril n=33	Candesartan n= 12	Ramipril	Candesartan
Sex	Male	Male	17	8	51.51%	66.66%
	Female	Perempuan	16	4	48.48%	33.33%
Age	18-65 years	36-65 tahun	27	7	81.81%	58.33%
	≥ 65 years	≥ 65 tahun	6	5	18.18%	41.66%
Comorbidities	With comorbidities	With comorbidities	3	0	90.9%	100%
	Without comorbidities	Without comorbidities	30	12	9.1%	0%
Status	Alive	Alive	14	4	42.42%	33.33%
	Death	Death	19	8	57.57%	66.66%

23 Based on the results of this study indicate that inpatient heart failure patients in RSUDP NTB who received therapy with the combination of ramipril were 17 people (51.52%) were male and 16 people (48.48%) were female. While those who received candesartan therapy were 8 people (66.67%) who were male and 4 people (33.33%) were female. These results indicate that more heart failure patients are male than female. Meanwhile, in age characteristics shows, 18-65 years of age most diagnosed with heart failure by 81.82% and age ≥ 65 years by 18.18%. While the characteristics of age at Candesartan are age 35-65 years as much as 58.34% and age ≥ 65 years as much as 41.66%. Based on characteristics of concomitant diseases in the ramipril combination group of 90.9% had concomitant diseases and as many as 9.1% who did not have concomitant diseases. Whereas in the candesartan combination group all patients had concomitant disease (100%). In both groups it was seen that the majority of heart failure patients in the were mostly

accompanied by concomitant diseases. Life status characteristics shows in the ramipril group patients mostly died (57.58%) compared to the number of living patients by 42.42%. Whereas in the candesartan group it was known that heart failure patients who died by 66.67% and patients living by 33.33% (**Table 1**).

### Direct Medical Cost

The description of medical expenses at the hospital can be used as input in determining the planning and control of hospital services. Costs that will be calculated in this study are direct medical costs including ramipril and candesartan drugs, other drugs, medical equipment costs, doctor's fees, nurse fees, laboratory fees and accommodation costs.

**Table 2. Medication cost between ramipril and candesartan combination**

Medication	Inpatient class	Number of patient	Item total cost (IDR)	Average medication cost (IDR)
Ramipril	VIP	5	71,773	14,355
	1	2	44,213	22,106
	2	7	77,017	11,002
	3	19	242,055	12,739
Candesartan	VIP	3	74,948	24,983
	1	1	26,964	26,964
	2	2	24,771	12,385
	3	6	123,401	20,566

Based on **table 2**, the average cost of drugs for heart failure patients using a combination of ramipril and candesartan combination has a different amount of costs. The difference in costs in each class is influenced by differences in length of stay, the number of drugs used and comorbidities besides heart failure and the types of drugs consumed so that it affects the costs that must be paid by the payer. The payer in this case is the Indonesian National Health Insurance Administering Agency (BPJS).

**Table 3. Others medication cost comparison between ramipril and candesartan combination**



Medication	Inpatient class	Number of patient	Item total cost (IDR)	Average medication cost (IDR)
Ramipril	VIP	5	1,918,688	383,738
	1	2	5,497,997	2,748,998
	2	7	766,951	110,993
	3	19	19,897,806	1,047,252
Candesartan	VIP	3	1,849,651	616,550
	1	1	318,754	318,754
	2	2	148,499	74,249
	3	6	1,991,553	331,925

Based on **table 3**, the average cost of other drugs for heart failure patients using the combination of ramipril and candesartan combination has a different amount of costs. Costs for drugs other than heart failure include medications used to treat comorbidities in addition to heart failure. Common comorbidities in heart failure patients are hypertension, diabetes mellitus, and myocardial infarction. Non-cardiovascular drugs used include ranitidine, lansoprazole, metformin, simvastatin, clopidogrel, and ceftriaxone.

**Tabel 4. Medical equipment cost comparison between ramipril and candesartan combination**

Medication	Inpatient class	Number of patient	Item total cost (IDR)	Average equipment cost (IDR)
Ramipril	VIP	5	573,594	114,719
	1	2	643,676	321,838
	2	7	620,930	88,704
	3	19	26,330,366	1,385,808
Candesartan	VIP	3	845,265	281,755
	1	1	219,409	219,409
	2	2	54,062	27,031
	3	6	1,140,748	190,124

Based on table 4, the average cost of medical devices for heart failure patients using a combination of ramipril and candesartan has a different amount of costs. The difference in the cost

of medical equipment in each class is influenced by differences in length of stay and the number of equipment used, so that it affects the cost that must be paid by the payer.

**Tabel 5. Average doctor visit and hospitalization cost comparison between ramipril and candesartan combination**

Medication	Inpatient class	Number of patient	Item total cost (IDR)	Average fee cost (IDR)
<b>Doctor visit fee</b>				
Ramipril	VIP	5	2,625,000	525,000
	1	2	1,020,000	510,000
	2	7	1,000,000	142,857
	3	19	3,620,000	190,526
Candesartan	VIP	3	3,875,000	1,291,667
	1	1	180,000	180,000
	2	2	220,000	110,000
	3	6	1,200,000	200,000
<b>Hospitalization cost</b>				
Ramipril	VIP	5	5,695,350	1,139,070
	1	2	5,898,600	2,949,300
	2	7	3,579,200	511,314
	3	19	17,974,973	946,051
Candesartan	VIP	3	3,647,133	1,215,711
	1	1	394,600	394,600
	2	2	741,223	370,616
	3	6	5,030,075	838,345

Based on table 5, the average cost of doctors fee and hospitalization cost using a combination of ramipril and candesartan combination has a different amount of costs. The difference in costs in each class is influenced by differences in length of stay, number of drugs, medical equipment and service (oxygen installation, blood sampling, adult infusion set), and comorbidities in addition to heart failure and types of drugs used, so that influenced the costs to be paid by the National Health Insurance (BPJS).

**Tabel 6. Average laboratory cost comparison between ramipril and candesartan combination**



<b>Medication</b>	<b>Inpatient class</b>	<b>Number of patient</b>	<b>Item total cost (IDR)</b>	<b>Average cost (IDR)</b>
<b>Laboratory cost</b>				
Kombinasi Ramipril	VIP	5	4.707,050	941.410
	1	2	1,645,000	822,500
	2	7	2,389,783	341,397
	3	19	8,306,340	422,965
Kombinasi Candesartan	VIP	3	1.749.000	583.000
	1	1	205,000	205,000
	2	2	389,000	194,500
	3	6	1,690,000	281,666
<b>Accommodation cost</b>				
Ramipril	VIP	5	6.500.000	1.300.000
	1	2	2,550,000	1,275,000
	2	7	1,875,000	267,857
	3	19	6,300,000	331,578
Candesartan	VIP	3	8.150.000	2.716.667
	1	1	300,000	300,000
	2	2	450,000	225,000
	3	6	1,450,000	241,666

Based on table 6, there is a difference in the cost of the laboratory and accommodation between ramipril and candesartan combination. Laboratory examination costs are preoperative and postoperative preparations, for patients who will undergo surgery required an individual examination based on the patient's condition. Differences in patient conditions cause different types, amounts and laboratory costs that must be incurred during treatment. Meanwhile, difference in accommodation cost due to class difference that affects the costs borne by patients. The cost for each class is different because the facilities of each room class are different. The cost of the VIP class is greater because the number of beds in the room has complete facilities compared to other treatment classes.

**Table 7. Average emergency and intensive cardiac care unit cost comparison between ramipril and candesartan combination**

Medication	Item total cost (IDR)	Average cost (IDR)
<b>Emergency department cost</b>		
Kombinasi Ramipril	2,900,000	241,667
Kombinasi Candesartan	1,000,000	142,857
<b>Intensive cardiac care unit cost</b>		
Kombinasi Ramipril	3,500,000	700,000
Kombinasi Candesartan	0	0

Based on table 7, the average cost of emergency room much higher in the ramipril combination Rp. 241,667 compared to the candesartan combination of Rp. 142,857. This is because the actual number of patients who get the ramipril combination more than patients who get the candesartan combination. Meanwhile, the average cost of the intensive cardiac care unit on the ramipril combination is Rp. 700,000, while for candesartan combinations Rp. 0. This happens due to samples in studies that received candesartan combination therapy none were treated in the intensive ward.


**Direct medical cost analysis**

**Table 8. Direct medical cost comparison between ramipril and candesartan**

Medication	Inpatient class	Number of patient	Total direct medical cost ( IDR )	Average direct medical cost ( IDR)	p
Ramipril	VIP	5	22,591,455	4,518,291	<b>0.570</b>
	1	2	19,049,486	9,524,743	
	2	7	11,908,881	1,701,269	
	3	19	84,951,540	4,471,134	
<b>Total</b>			<b>138,501,362</b>	<b>4,197,011</b>	
Candesartan	VIP	3	20,290,997	6,763,666	
	1	1	1,744,727	1,744,727	

	2	2	2,027,555	1,013,778
	3	6	13,125,777	2,187,630
<b>Total</b>			<b>37,189,056</b>	<b>3,099,088</b>
<b>Mean difference of direct medical cost</b>	<b>IDR 1,097,923</b>			

Based on table 8, the average direct medical cost of patients using the Ramipril combination amounted to IDR 4,197,011 while the average direct medical costs of patients using the candesartan combination amounted to IDR 3,099,088. The difference between the average direct medical costs between a combination of ramipril and candesartan is Rp. 1,097,088. These results can illustrate that candesartan drugs are more cost-effective than ramipril drugs. Candesartan can provide lower economic value in the treatment of heart failure compared with ramipril. Meanwhile, after t-test comparison we found  $p=0.570$  ( $p<0.05$ ) which means there is no significant difference between the average direct medical costs in patients using the ramipril combination compared with the candesartan combination. However, mathematically the cost of candesartan is more efficient compared to ramipril. Graph comparison between all cost parameter can be seen in figure 1.



**Figure 1. Comparison graph between all study parameter between ramipril and candesartan combination.**

## Discussion

According to Choi et al. the incidence of heart failure is more common in men than women, this is related to lifestyle and other risk factor such as smoking and alcohol consumption.<sup>19</sup> Study

by Mosterd et al. age is one of the factors that influence the incidence of heart failure, older age contribute as a factor for developing heart failure by 10% if it is not matched by a healthy lifestyle.<sup>7</sup> Lawson et al. study >85% of patients with heart failure have comorbidities or comorbidities.<sup>20</sup> The World Health Organization (WHO) notes that 17.9 million people worldwide die from cardiovascular disorders with a percentage of 31% of deaths worldwide.<sup>10</sup>

The cost of each patient varies due to the length of time the patient has been inpatient and treatment. The results obtained are similar to Rahmawati et al. research which states that the use of candesartan drugs is more efficient than the use of other medications for treatment in patients with heart failure.<sup>21</sup>

Another study conducted by Schadlich et al. Regarding cost effectiveness of ramipril in patients with heart failure in myocardial infarction in Germany, there is a variation in the value of ramipril that is 2500 to 8300 deutschmarks (DM) per life-year gained and ramipril shows a favourable cost incremental cost-effectiveness ratio in heart failure treatment compared to placebo.<sup>22</sup>

Another study conducted in Indonesia by Baroroh et al. Regarding the cost-effectiveness of candesartan compared to the combination of candesartan amlodipine in patients with hypertension in the setting of an outpatient clinic, it shows that candesartan alone has a better cost-effectiveness of IDR 580,993 in one month of treatment.<sup>23</sup>

## Conclusion

We concluded there was no significant difference between the average direct medical costs in patients using the ramipril combination compared with the candesartan combination. Economically the candesartan combination drug saves more costs (IDR 3,099,088) compared to the ramipril combination (IDR 4,197,011) with an average difference in cost of Rp. 1,097,923.

## Conflict of interest

The authors declare there is no conflict of interest regarding publication of current study.

## Funding

The current study doesn't receive any specific grant from government or any private sectors.

## Ethical statement

This study was conducted after obtaining ethical clearance from director of West Nusa Tenggara Regional Hospital, with ethical clearance reference number number 070/2037/RSUDP NTB.

## References

1. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure

- 5  
2008: the task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the heart failure association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). *Eur Heart J*. 2008;29(19):2388–442.
2. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. Heart disease and stroke statistics–2014 update: a report from the American Heart Association. *Circulation*. 2014;129(3):e28–e292.
3. Ponikowski P, Voors AA, Anker SD, et al. 2015 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur Heart J*. 2016;37:2129–2200.
4. Kim MS, Lee JH, Kim EJ, et al. Korean guidelines for diagnosis and management of chronic heart failure. *Korean Circ J*. 2017;47:555–643.
5. Youn JC, Han S, Ryu KH. Temporal trends of hospitalized patients with heart failure in Korea. *Korean Circ J*. 2017;47:16–24.
6. Aimin Shi, Ziqi Tao, Peng Wei, Jing Zhao. Epidemiological aspects of heart diseases. *Exp Ther Med*. 2016;12(3):1645–1650.
7. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. *Heart* 2007;93:1137–1146.
8. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. *N Engl J Med*. 2006;355:251–259.
9. Lee JH, Lim NK, Cho MC, Park HY. Epidemiology of heart failure in Korea: present and future. *Korean Circ J*. 2016;46:658–664.
10. World Health Organization. Cardiovascular Diseases. Available at: [https://www.who.int/health-topics/cardiovascular-diseases/#tab=tab\\_1](https://www.who.int/health-topics/cardiovascular-diseases/#tab=tab_1).
11. Bui LB, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure, *Nature Reviews Cardiology*. 2011;8:30–41.
12. Liao L, Allen LA, Whellan DJ. Economic burden of heart failure in the elderly. *Pharmacoeconomics*. 2008;26(6):447–62.
13. Cook C, Cole G, Asaria P, Jabbour R, Francis DP. The annual global economic burden of heart failure. *Int J Cardiol*. 2014;171(3):368–76.
- 4  
14. Reed SD, Whellan DJ, Li Y, Friedman JY, Ellis SJ, Pina IL, et al. Economic evaluation of the HF-ACTION (heart failure: a controlled trial investigating outcomes of exercise training) randomized controlled trial: an exercise training study of patients with chronic heart failure. *Circulation Cardiovascular quality and outcomes*. 2010;3(4):374–81.
- 16  
15. Bundkirchen A, Schwinger RHG. Epidemiology and economic burden of chronic heart failure. *European Heart Journal, Supplement*. 2004;6(D):D57–60.

16. Pocock SJ, Ariti CA, McMurray JJ, Maggioni A, Kober L, Squire IB, et al. Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. *Eur Heart J*. 2013;34(19):1404–13.
17. Drummond M, Sculpher M, Claxton K, Stoddart G, Torrance G. *Methods for The Economic Evaluation of Health Care Programmes*. 4th ed. 2015.
18. Cameron D, Ubels J, Norstrom F. On what basis are medical cost-effectiveness thresholds set? Clashing opinions and an absence of data: a systematic review. *Global Health Action*. 2018;11(1):1447828.
19. Hong-Mi Choi, Myung-Soo Park<sup>2</sup>, and Jong-Chan Youn. Update on heart failure management and future directions. *Korean J Intern Med*. 2019;34:11-43.
20. Lawson CA, Solis-Trapala I, Dahlstrom U, Mamas M, Jaarsma T, Kadam UT, et al. (2018) Comorbidity health pathways in heart failure patients: A sequences-of-regressions analysis using cross-sectional data from 10,575 patients in the Swedish Heart Failure Registry. *PLoS Med* 15 (3): e1002540. <https://doi.org/10.1371/journal.pmed.1002540>
21. Rahmawati<sup>7</sup>, Nurwahyuni A. Analysis of the Minimal Cost of Antihypertensive Medication between the Combination of Ramipril-Spironolactone with Valsartan in Congestive Heart Failure Patients at XY Hospital in Jakarta in 2014. *Journal of Indonesian Health Economics*. 2017;1(4):191-200.
22. Schädlich PK, Huppertz E, Brecht JG. Cost-effectiveness analysis of ramipril in heart failure after myocardial infarction. Economic evaluation of the Acute Infarction Ramipril Efficacy (AIRE) study for Germany from the perspective of Statutory Health Insurance. *Pharmacoeconomics*. 1998;14(6):653-669. doi:10.2165/00019053-199814060-0006.
23. Baroroh F, Sari A, Masruroh N. Cost Effectiveness Analysis of Candesartan Therapy in Comparison to Candesartan-Amlodipine Therapy on Hypertensive Outpatients. *Open Access Maced J Med Sci*. 2019;7(22):3837-3840. Published 2019 Nov 14. doi:10.3889/oamjms.2019.515

# Comparison of direct medical cost between ramipril and candesartan in hospitalized acute decompensated heart failure at West Nusa Tenggara Regional Hospital

## ORIGINALITY REPORT

19%

SIMILARITY INDEX

13%

INTERNET SOURCES

13%

PUBLICATIONS

15%

STUDENT PAPERS

## PRIMARY SOURCES

1	<a href="http://www.thecommunityguide.org">www.thecommunityguide.org</a> Internet Source	1%
2	Submitted to Macquarie University Student Paper	1%
3	<a href="http://jaumepuigjunoy.cat">jaumepuigjunoy.cat</a> Internet Source	1%
4	Gemma E Shields, Adrian Wells, Patrick Doherty, Anthony Heagerty, Deborah Buck, Linda M Davies. "Cost-effectiveness of cardiac rehabilitation: a systematic review", Heart, 2018 Publication	1%
5	R Bhidayasiri. "Chorea and related disorders", Postgraduate Medical Journal, 2004 Publication	1%
6	<a href="http://jthc.tums.ac.ir">jthc.tums.ac.ir</a> Internet Source	1%
7	Cyntiya Rahmawati, Atik Nurwahyuni. "Analisis	



Minimalisasi Biaya Obat Antihipertensi antara Kombinasi Ramipril-Spironolakton dengan Valsartan pada Pasien Gagal Jantung Kongestif di Rumah Sakit Pemerintah XY di Jakarta Tahun 2014", Jurnal Ekonomi Kesehatan Indonesia, 2017

Publication

1%

8

Hyemin Ku, Wook-Jin Chung, Hae-Young Lee, Byung-Soo Yoo, Jin-Oh Choi, Seoung-Woo Han, Jieun Jang, Eui-Kyung Lee, Seok-Min Kang. "Healthcare Costs for Acute Hospitalized and Chronic Heart Failure in South Korea: A Multi-Center Retrospective Cohort Study", Yonsei Medical Journal, 2017

Publication

1%

9

"Contributed Poster Presentations", Value in Health, 11/2003

Publication

1%

10

Submitted to South University

Student Paper

1%

11

Submitted to Kaplan University

Student Paper

1%

12

Lis Neubeck, Tina Hansen, Tiny Jaarsma, Leonie Klompstra, Robyn Gallagher. "Delivering healthcare remotely to cardiovascular patients during COVID-19", European Journal of Cardiovascular Nursing, 2020

1%

---

13	<a href="http://eprints.ums.ac.id">eprints.ums.ac.id</a> Internet Source	1%
14	<a href="http://diglib.tums.ac.ir">diglib.tums.ac.ir</a> Internet Source	1%
15	<a href="http://www.pharmacy.gov.my">www.pharmacy.gov.my</a> Internet Source	1%
16	François Alla. "Epidemiology and Management of Acute Heart Failure Syndromes in Europ", Acute Heart Failure, 2008 Publication	1%
17	"Yoga for improving functional capacity, quality of life and cardiovascular outcomes in people with heart failure", Cochrane Database of Systematic Reviews, 2016. Publication	1%
18	<a href="http://www.repository.cam.ac.uk">www.repository.cam.ac.uk</a> Internet Source	1%
19	<a href="http://lib.fkik.untad.ac.id">lib.fkik.untad.ac.id</a> Internet Source	<1%
20	<a href="http://onlinelibrary.wiley.com">onlinelibrary.wiley.com</a> Internet Source	<1%
21	<a href="http://lup.lub.lu.se">lup.lub.lu.se</a> Internet Source	<1%

---

22	Submitted to Grand Canyon University Student Paper	<1%
23	"Contributed Podium Presentations", Value in Health, 11/2006 Publication	<1%
24	Submitted to University of San Francisco Student Paper	<1%
25	Submitted to University of Westminster Student Paper	<1%
26	Mohamed Djerioui, Youcef Brik, Mohamed Ladjal, Bilal Attallah. "Neighborhood Component Analysis and Support Vector Machines for Heart Disease Prediction", Ingénierie des systèmes d information, 2019 Publication	<1%
27	e-sciencecentral.org Internet Source	<1%
28	www.nejm.org Internet Source	<1%
29	Submitted to University of Suffolk Student Paper	<1%
30	Daniel L Riddle, Francis J Keefe, Dennis Ang, Khaled J et al. "A phase III randomized three-arm trial of physical therapist delivered pain coping skills training for patients with total knee	<1%

arthroplasty: the KASTPain protocol", BMC  
Musculoskeletal Disorders, 2012

Publication

31

Arthorn Riewpaiboon. "Diabetes Cost Model of a Hospital in Thailand", Value in Health, 7/2007

Publication

<1%

32

Submitted to University of the Pacific

Student Paper

<1%

33

Submitted to Aspen University

Student Paper

<1%

34

Submitted to Cranfield University

Student Paper

<1%

35

Submitted to University of Leicester

Student Paper

<1%

36

Submitted to Des Moines University

Student Paper

<1%

37

[annals.org](http://annals.org)

Internet Source

<1%

38

[doczz.net](http://doczz.net)

Internet Source

<1%

39

[www.theplantbasedeater.com](http://www.theplantbasedeater.com)

Internet Source

<1%

40

Eristina, T M Andayani, R A Oetari. "Direct medical cost and utility analysis of diabetics

<1%

outpatient at Karanganyar public hospital", IOP  
Conference Series: Materials Science and  
Engineering, 2017

Publication

---

41

Mark A. Hlatky, Paul A. Heidenreich. "The Year  
in Epidemiology, Health Services Research, and  
Outcomes Research", Journal of the American  
College of Cardiology, 2011

Publication

---

<1%

42

Mi-Hyang Jung, Hack-Lyoung Kim, Jae Hyuk  
Choi, Sunki Lee et al. "Heart failure awareness  
in the Korean general population: Results from  
the nationwide survey", PLOS ONE, 2019

Publication

---

<1%

43

Submitted to University of Technology, Sydney

Student Paper

---

<1%

44

Torbjørn Omland. "Advances in congestive heart  
failure management in the intensive care unit: B-  
type natriuretic peptides in evaluation of acute  
heart failure", Critical Care Medicine, 2008

Publication

---

<1%

---

Exclude quotes

Off

Exclude matches

Off

Exclude bibliography

Off



Editor Bali Medical Journal &lt;editorbalimedicaljournal@gmail.com&gt;

---

**revision required (Bali Med J 1871)**

6 messages

---

**Editor Bali Medical Journal** <editorbalimedicaljournal@gmail.com>  
To: nuqi.gra@gmail.com

Sat, May 23, 2020 at 8:41 AM

Dear Authors,

Thank you for submitting your article entitled: "**Comparison of direct medical cost between ramipril and candesartan in hospitalized acute decompensated heart failure at West Nusa Tenggara Regional Hospital**"

Based on our author guidelines, Your article fulfilled the minimal required structure, <https://www.balimedicaljournal.org/index.php/bmj/pages/view/authorguidelines>

In order to have a better-structured article, we suggest you edit based on a checklist and the collection in our archive (<https://www.balimedicaljournal.org/index.php/bmj/issue/archive>).

According to the new International regulation, please fulfill the requirements below:

1. Please include Ethical clearance number/statement at the end of the manuscript if the bacteria were collected from clinical isolates (**confirmed**).
2. Please state your conflict of interest in the paper. (**unconfirmed**)
3. Please state the funding (if any) in your paper. (**unconfirmed**)
4. Please state each author's contribution. (**unconfirmed**)
5. Based on our proofreading application, we detected 184 critical grammatical errors.

According to our initial review, your article needs Minor Revision. Please revise your article and send it back to us in **7 days**

Please find the attached revision note for your manuscript and do not forget to full fill the icjme author list and contributor list

Thank you for trusting us with your hard work and we are looking forward to your response.

Warm regards,

Executive Editor BaliMedJ

--

**Bali Medical Journal (BaliMedJ)**

**P-ISSN:** 2089-1180

**E-ISSN** 2302-2914

Indexed at:

[Web of Science \(WOS\) Clarivate Analytics](#)




[SCOPUS Elsevier](#)

[All Indexing Organisation](#)




---

### 3 attachments

-  **1871-BMJ-Commentaries.doc**  
95K
-  **Contribution Details (3).docx**  
15K
-  **ICJME author ship criteria.pdf**  
658K

---

**nurul qiyaam** <nuqi.gra@gmail.com>  
To: Editor Bali Medical Journal <editorbalimedicaljournal@gmail.com>

Mon, May 25, 2020 at 2.32 PM

Dear Editoria Team of Bali Med J

Thank you for your advice revision, soon I will sent the revision along with ICJME author list and contributor list

Best regards  
Nurul Qiyaam  
[Quoted text hidden]

---

**nurul qiyaam** <nuqi.gra@gmail.com>  
To: Editor Bali Medical Journal <editorbalimedicaljournal@gmail.com>

Mon, Jun 8, 2020 at 11:02 AM

Dear Editoria Team of Bali Med J




I have sent the revision trough out the system, I also attached the revised manuscript along with the ICJME author list and contributor list in the attached ment below

Warm and regards

Nurul Qiyaam  
[Quoted text hidden]

---

### 3 attachments

-  **Contribution Details (3).docx**  
15K
-  **ICJME author ship criteria.pdf**  
658K
-  **1871-BMJ-naskah.docx**  
53K

---

**Editor Bali Medical Journal** <editorbalimedicaljournal@gmail.com>  
To: nurul qiyaam <nuqi.gra@gmail.com>

Tue, Jun 9, 2020 at 10:33 AM

Dear Author

We had received your full revision



Soon we will come back for final decision

Best and regards  
 Managing Editor Bali Med J  
 [Quoted text hidden]

**Editor Bali Medical Journal** <editorbalimedicaljournal@gmail.com>  
 To: nurul qiyaam <nuqi.gra@gmail.com>

Wed, Jun 24, 2020 at 2:12 PM

Dear author: please find the attached acceptance letter and invoice billing for your manuscript

### Letter of Acceptance

24 June 2020

**Dear: Nurul Qiyaam\*, Baiq Leny Nopitasari, Cyntiya Rahmawati, Baiq Nurbaety, Emasiska Ajeng Pratiwi**

Pharmacy Department, Faculty of Medicine, Universitas Muhammadiyah Mataram, Indonesia

\*Corresponding email author: [nuqi.gra@gmail.com](mailto:nuqi.gra@gmail.com)

I am very excited to accept your paper entitled:

**“Comparison of direct medical cost between ramipril and candesartan in hospitalized acute decompensated heart failure at West Nusa Tenggara Regional Hospital.”**

Your paper will be published in the issue of Vol. 9 Number 2, 2020.

<http://dx.doi.org/10.15562/bmj.v9i2.1871>

(Online Link: <http://balimedicaljournal.org/index.php/bmj/article/view/1871>).

And it usually takes 2 to 4 months for your journal to show up at Google Scholar, but if you need it fast, you may add it up manually using your google scholar account. The CrossRef and DOI number usually activate in 3 until 6 months.

Bali Medical Journal is indexed in Web of Sciences (Thomson Reuters) and many other indexing organization: <http://balimedicaljournal.org/index.php/bmj/pages/view/indexing>

1. Web of Science (Clarivate Analytics)
2. USA National Library of Medicine (Pubmed)
3. NIH National Institutes of Health
4. HINARI Research in Health
5. International Committee of Medical Journal Editors
6. DOAJ Directory of Open Acces Journals
7. SINTA-Science and Technology Index
8. Portal Garuda
9. Google Scholar
10. DOI Crossref
11. EBSCO Open Science Directory
12. Sherpa/Romeo
13. Ulrichsweb.com™ [Proquest]
14. InCites Journal Citation Reports (Web of Science)
15. Harvard Library
16. Index Copernicus
17. National Library of Australia
18. University of Denmark
19. Library of Science and Technology (China)
20. ETH Bibliothek (Switzerland)
21. SJIF Journal Rank
22. Science Impact Factor (SIF)
23. Genamics
24. ASEAN Citation Index (ACI)
25. UDL-Edge (Malaysia)

Please do not hesitate to contact us if you need anything. It has been a pleasure for us to proofread and edit your work, and we are looking forward to your colleagues and your other papers in the near future

**2 attachments**

 **38947\_612 Letter of Acceptance 1871 Nurul Qiyaam.pdf**  
260K

 **INV2-MH39-EBSC-6RCR-BQ98.pdf**  
30K

---

**nurul qiyaam** <nuqi.gra@gmail.com>  
To: Editor Bali Medical Journal <editorbalimedicaljournal@gmail.com>

Sat, Jun 27, 2020 at 12:20 AM

Dear Editorial Board Member of Bali Med J

Thank you for the acceptance letter, its an honor to be published in your journal

Please find the attached payment proof for my manuscript

Warm regards  
Nurul Qiyaam

Pada tanggal Rab, 28 Sep 2022 pukul 22.47 Editor Bali Medical Journal <editorbalimedicaljournal@gmail.com> menulis:

>

[Quoted text hidden]



**1871-bmj-payment.jpeg**  
157K

STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	<b>Item No</b>	<b>Recommendation</b>	<b>Reported on page No</b>
<b>Title and abstract</b>	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract	The study design has already indicated in the abstract
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	The abstract has presented informative and balanced summary of the study
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	The background of the study has been clearly explained.
Objectives	3	State specific objectives, including any prespecified hypotheses	The objective(s) of the study clearly stated in the introduction section
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	Clearly presented in the paper
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	The setting, location, and relevant dates has been described
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	The inclusion and exclusion criteria not clearly described.
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	The outcome of the study has been stated in the paper
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Clearly described in the paper
Bias	9	Describe any efforts to address potential sources of bias	Not described
Study size	10	Explain how the study size was arrived at	Not described in the paper
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Data analysis has been clearly described using descriptive, independent t-test or mann whitney test
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	The statistical method has been described
		(b) Describe any methods used to examine subgroups and interactions	N/A
		(c) Explain how missing data were addressed	Not explained in the paper
		(d) If applicable, describe analytical methods taking account of sampling strategy	N/A
		(e) Describe any sensitivity analyses	N/A
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined	Described well in the result section

		for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	
		(b) Give reasons for non-participation at each stage	Not described
		(c) Consider use of a flow diagram	Not described
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	The characteristics has been described in table 1
		(b) Indicate number of participants with missing data for each variable of interest	Not explicitly stated, but can be inferred
Outcome data	15*	Report numbers of outcome events or summary measures	N/A
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Descriptive method with spearman test, and chi-square test.
		(b) Report category boundaries when continuous variables were categorized	N/A
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	All analysis performed has been well presented
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	Well described
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	The limitation not stated at the discussion section
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	The interpretation of the results obtained has been carefully interpreted with comparison of results of similar studies
Generalisability	21	Discuss the generalisability (external validity) of the study results	Not clearly described
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Not described

\*Give information separately for exposed and unexposed groups.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at

<http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

In order to make current manuscript better we advice the following revision

1. Please not use all capital in Running title
2. Please divide the abstract into intro, method, result, and conclusion.
3. Kindly describe the aim of the study at the introduction section
4. Kindly describe the rationale of the study at the introduction section (why we have to evaluate cost effectiveness between Ramipril and candesartan since bot are very similliar medication belong to ACE-I and ARB group)
5. Describe the inclusion and exclusion criteria at the method section.
6. Make sure to add limitation of the study at the end of discussion section.
7. Kindly double check your manuscript all the reference must be cited in the text or vice versa.
8. Any comparison regarding simmiliar study must be added at the discussion section, may be any comparison from Indonesia regarding cost effectiveness of cadesartan and ramipril
9. Make sure to add conflict of interest, funding, acknowledgement, and ethical aspect of the study. Since those kind of thing are very important in journal article.

**Journal:**

1. Thomas MC. Diuretics, ACE inhibitors and NSAIDs – the triple whammy. *Med J Aust.* 2000;172:184–185.
2. Guilbert TW, Morgan WJ, Zeiger RS, Mauger DT, Boehmer SJ, Szeffler SJ, et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. *N Engl J Med.* 2006;354:1985–97.

**Sitasi WEB:**

1. Thomas ABC. Vancouver reference style [Internet]. Oaktown (ON): University of Oaktown, Department of Science; 2007 Nov 1 [updated 2008 Jan 11; cited 2008 Feb 19]. Available from: <http://www.org-name.org>

**Chapter di dalam buku:**

1. Bjork CE Jr, McLeod RD. Formatting citations. In: Laurent B 3rd, Cool JR, editors. *A history of citations and references.* 5th ed. Geneva (Switzerland): Tangelo Press; 2006. p. 93-7.

**Buku utuh:**

1. Thomas ABC, editor. *Vancouver reference style: a history.* New York: Z&E Publishers; 2007. 582 p.